iShares Biotechnology ETF
IBB

$147.92

1.04%

Market Cap: $7.7B

0

Funds holding %

of 6,710 funds

–

Analysts bullish %

Fund manager confidence

Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)

0% more funds holding in top 10

Funds holding in top 10: 11 [Q1] → 11 (+0) [Q2]

0% less funds holding

Funds holding: 878 [Q1] → 875 (-3) [Q2]

4% less first-time investments, than exits

New positions opened: 79 | Existing positions closed: 82

2.82% less ownership

Funds ownership: 73.81% [Q1] → 70.99% (-2.82%) [Q2]

7% less capital invested

Capital invested by funds: $5.67B [Q1] → $5.29B (-$385M) [Q2]

38% less repeat investments, than reductions

Existing positions increased: 200 | Existing positions reduced: 320

76% less call options, than puts

Call options by funds: $301M | Put options by funds: $1.27B

See Fund Rankings

Research analyst outlook

We haven’t received any recent analyst ratings for IBB.

See Analyst Rankings

Financial journalist opinion

Based on 3 articles about IBB published over the past 30 days

Biotech Breakout: Stocks for Your Watchlist

After a prolonged consolidation and downtrend following the pandemic-driven surge, the biotechnology sector is readying for a potential breakout and shifting its narrative. Represented by the iShares Biotechnology ETF NASDAQ: IBB, the sector has turned a significant corner, with previous resistance levels becoming support, setting the stage for a potential momentum shift.

Biotech Breakout: Stocks for Your Watchlist

Biotech Stocks Are Showing Signs of Life. Why the Rally Could Continue.

Thanks to the prospect of lower interest rates, shares of biotech companies have doubled the gains of the broad market over the past few months.

Biotech Stocks Are Showing Signs of Life. Why the Rally Could Continue.

The Motley Fool

3 ETFs for Growth Investors to Buy and Hold for Decades

Exchange-traded funds aren't just for risk-averse investors. Many funds can give exposure to some great growth stocks.

3 ETFs for Growth Investors to Buy and Hold for Decades

CNBC Television

Biotech stocks will get a tailwind from rate cuts, says Stempoint's Michelle Ross

Michelle Ross, Stempoint Capital, joins 'Closing Bell' to discuss Eli Lilly after the stock saw a slight dip after rallying.

Biotech stocks will get a tailwind from rate cuts, says Stempoint's Michelle Ross

Zacks Investment Research

Is iShares Biotechnology ETF (IBB) a Strong ETF Right Now?

The iShares Biotechnology ETF (IBB) made its debut on 02/05/2001, and is a smart beta exchange traded fund that provides broad exposure to the Health Care ETFs category of the market.

Is iShares Biotechnology ETF (IBB) a Strong ETF Right Now?

Zacks Investment Research

Should You Invest in the iShares Biotechnology ETF (IBB)?

Designed to provide broad exposure to the Healthcare - Biotech segment of the equity market, the iShares Biotechnology ETF (IBB) is a passively managed exchange traded fund launched on 02/05/2001.

Should You Invest in the iShares Biotechnology ETF (IBB)?

Analyst is 'extremely bullish' on biopharma

Pfizer (PFE) and Merck (MRK) reported their second quarter earnings, with both companies beating expectations. Grey Ghost Advisors CEO Meghan Fitzgerald joins Catalysts to give insight into Pfizer and Merck's recent earnings and what the reports signal about the broader healthcare sector.

Analyst is 'extremely bullish' on biopharma

Key Stock Market ETFs Hanging Tough Amidst Volatility

Here we are, another week and another notch on the bull market belt. Last weekend, we were very bullish coming into this past week on Small Caps, Biotechnology and Regional Banks.

Key Stock Market ETFs Hanging Tough Amidst Volatility

iShares Biotechnology ETF: Significant Upside Potential As Sector Gains Momentum

Biotechnology companies experienced an optimistic bullish cycle in 2020-2021, leading to outperformance of the Biotech index. But the cycle of interest rate increases taking place since 2022 has caused several Biotech companies to observe cash flow issues. Advances in AI, machine learning, and generative AI are likely to accelerate drug discovery processes and optimize operations in the biotech and pharma sectors, leading to growth opportunities.

iShares Biotechnology ETF: Significant Upside Potential As Sector Gains Momentum

CPI Data Sparks Rally in Biotech Stocks

The biotech sector has significantly lagged behind the overall market and its leading sector, technology, year-to-date. However, following the release of the CPI data on Thursday, the biotech sector, represented by the iShares Biotechnology ETF NASDAQ: IBB, experienced a significant breakout above a multi-year resistance level.

CPI Data Sparks Rally in Biotech Stocks

See News Rankings